Bristol-Myers Squibb Quarterly Cash Flow Statement
NYSE: BMYHealthcareDrug Manufacturers - GeneralUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Bristol-Myers Squibb free cash flow
In the quarter ended Jun 30, 2026, Bristol-Myers Squibb generated $3.39 billion of operating cash flow and spent $305.0 million on capital expenditures. That left free cash flow of $3.09 billion, a free-cash-flow margin of 23.8% of revenue. Free cash flow was down 13.2% from the prior year's $3.56 billion.
Bristol-Myers Squibb returned $1.29 billion to shareholders through dividends, equal to 42% of free cash flow. Free cash flow covered dividend payments 2.4 times.
Summary generated from market data by MetaCap's automated system. Methodology
Bristol-Myers Squibb cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | 3.32B | 2.68B | 1.08B | 2.19B | 1.31B | 2.46B | 76.00M | 1.22B | 1.68B | -11.91B | 1.76B | 1.93B |
| Net Income growth (YoY) | +152.55% | +8.77% | +1327.63% | +80.66% | -22.03% | — | -95.69% | -37.18% | -18.92% | -625.28% | -12.99% | +20.27% |
| Depreciation & Amortization | 594.00M | 594.00M | 977.00M | 1.01B | 1.01B | 1.01B | 1.88B | 2.59B | 2.60B | 2.53B | 2.46B | 2.44B |
| Stock-Based Compensation | 135.00M | 146.00M | 133.00M | 139.00M | 137.00M | 144.00M | 120.00M | 129.00M | 125.00M | 133.00M | 127.00M | 132.00M |
| Change in Working Capital | -1.25B | 2.11B | 0 | 225.00M | -467.00M | -239.00M | 835.00M | 69.00M | -1.50B | 561.00M | -261.00M | -771.00M |
| Operating Cash Flow | 3.39B | 1.10B | 1.97B | 6.31B | 3.92B | 1.95B | 4.44B | 5.59B | 2.33B | 2.83B | 4.25B | 4.75B |
| Capital Expenditures | -305.00M | -347.00M | -370.00M | -320.00M | -361.00M | -260.00M | -378.00M | -324.00M | -262.00M | -284.00M | -330.00M | -342.00M |
| Investing Cash Flow | -1.61B | -131.00M | -1.46B | -1.70B | -473.00M | -499.00M | -196.00M | -219.00M | -1.32B | -19.62B | -1.35B | -410.00M |
| Dividends Paid | -1.29B | -1.28B | -1.26B | -1.26B | -1.26B | -1.26B | -1.22B | -1.22B | -1.22B | -1.21B | -1.16B | -1.19B |
| Share Repurchases | — | — | — | — | — | — | 0 | 0 | 0 | 0 | 0 | -4.00B |
| Debt Issued | — | — | 5.74B | 0 | 0 | 0 | 0 | 0 | 0 | 12.88B | — | 0 |
| Debt Repaid | -1.22B | -500.00M | -10.07B | -229.00M | -643.00M | 0 | 0 | -2.48B | -395.00M | 0 | -2.00B | 0 |
| Financing Cash Flow | -2.63B | -1.56B | -6.03B | -1.49B | -1.84B | -993.00M | -1.64B | -3.85B | -4.02B | 14.64B | 967.00M | -5.16B |
| Net Change in Cash | -861.00M | -635.00M | -5.51B | 3.12B | 1.74B | 528.00M | 2.45B | 1.60B | -3.04B | -2.19B | 3.95B | -857.00M |
| Free Cash Flow | 3.09B | 757.00M | 1.60B | 5.99B | 3.56B | 1.69B | 4.06B | 5.27B | 2.06B | 2.55B | 3.92B | 4.41B |
This table shows 12 quarterly periods of Bristol-Myers Squibb's cash flow statement, from Q2 2026 back to Q3 2023, across 14 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow BMY's reporting calendar. What is a cash flow statement?